Submit Deal

Announced

7 Sep 2022

Completed

7 Sep 2022

Viatris completed the acquisition of a 5.1% stake in Syngene from Biocon for $153m.

Synopsis

Viatris, a global pharmaceutical company, completed the acquisition of a 5.1% stake in Syngene, an innovation-led contract research, development and manufacturing organization, from Biocon, an Indian biopharmaceutical company, for $153m.

Principals

target

SYNGENE

bidder

VIATRIS

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Sort

Seller Team (2)

jonathan hunt

CEO at SYNGENE

Manager

target

Deals

£ 137 M

Total Value

sibaji biswas

CFO at SYNGENE

Manager

target

Deals

£ 137 M

Total Value

Bidder Team (2)

sanjeev narula

CFO at VIATRIS

Manager

bidder

Deals

£ 5.27 B

Total Value

michael goettler

CEO at VIATRIS

Manager

bidder

Deals

£ 18.90 B

Total Value

Vendor Team (4)

indranil sen

CFO at BIOCON BIOLOGICS LTD

Manager

vendor

Deal

£ 137 M

Total Value

siddharth mittal

CEO at BIOCON BIOLOGICS LTD

Manager

vendor

Deal

£ 137 M

Total Value

chintan kothari

Executive Director at Avendus

Financial Advisor

vendor

Deals

£ 427 M

Total Value

gaurav sood

Managing Director & Head, Equity Capital Markets at Avendus

Financial Advisor

vendor

Deals

£ 495 M

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy